



ALCOR WEALTH
CONNECTING AND FOSTERING
GLOBAL COMMUNITY

Alcor Drug Discovery Platform

30TH SEPTEMBER 2021



Conference Agenda

1:15 – 1:30 (GMT) CHAIRMAN'S WELCOME REMARKS

1:30 - 2:00 PRESENTATION NO.1:

Peptide Drug Discovery & Development



Tomi Sawyer

**Chief Drug Hunter
& President**

**Maestro
Therapeutics**


2:00 - 2:30 PRESENTATION NO.2:

**NBD Platform: a disruptive software for Drug Design,
Enzyme Engineering & Targeting**



Ali Hosseini

**Sales and Business
Development**




2:30 - 3:00 PRESENTATION NO.3:

**Structure based drug discovery on membrane
proteins enabled by recent developments in X-ray
and Cryo-EM methods.**



Michael Hennig

CEO



Conference Agenda

3:00 - 3:30 PRESENTATION NO.4:

Data Management for Collaborative Drug Discovery



Susana Tomasio
Senior Application Scientist



3:30 - 4:00 PRESENTATION NO.5:

Recent advancement on Drug Discovery Science and Technology




Domingo Gargallo-Viola
CEO & CSO



4:00 - 4:30 PRESENTATION NO.6:

Artificial Intelligence in Drug Discovery :Data-driven and Machine Learning Approaches:



Peter Henstock
Machine Learning & AI Lead

Discussing the role of AI/ML AND its future aspect in Drug Discovery

Outlining the needs for ML Modeling in when increasing the level of automation in drug discovery

Applications of AI/ML in Drug Discovery



Conference Agenda

4:30 - 5:00 PRESENTATION NO.7:

Healing the Body and the Mind; from a Holistic Energy Perspective

What is Energy Diagnosis and Treatment?

Today, there are more Energy Healing Device and Healing Modality options available to the patient, than ever before. Star Trek's science fiction Tricorder and BioBed are nearly today's science fact.

We will explore the current landscape of energy healing devices and healing modalities. For the patient, energy diagnosis and treatment are both non-invasive and painless



Paul Levin

Emotional Breakthrough Mentor




5:00 - 5:30 PANEL DISCUSSION

Repurposing therapeutics for COVID-19: Rapid prediction of commercially available drugs through machine learning and docking: A review of COVID-19 biomarkers and drug targets: resources and tools

Artificial intelligence in COVID-19 drug repurposing
Lessons from the COVID-19 pandemic for advancing computational drug repurposing strategies



Future Directions and Potential treatment for COVID-19

Panel Moderator



Alexander Spicer

Business Development and Licensing Director




Eric Halioua

CEO




Philippe Moingeon

Head of therapeutic area immuno-inflammation



Alexander Spicer

Business Development and Licensing Director



Abhit Singh

VP, Medical Affairs, Intromune Therapeutics

